This project intends to explore the therapeutic efficacy of human serum albumin in mitigating postoperative cerebral edema and enhancing clinical outcomes following mechanical thrombectomy in patients with acute anterior circulation large-core ischemic stroke.
Age 18-80 years old.
Acute ischemic stroke patients with NIHSS score ≥ 6.
Pre-stroke mRS (modified Rankin Scale) score ≤ 1.
Onset of symptoms to presentation within 24 hours, including wake-up strokes or strokes without witnessed onset; the time of symptom onset is defined as the "last seen normal" time.
Intracranial hemorrhage confirmed by head CT or MRI.
Pre-stroke mRS score > 2.
Severe allergy or absolute contraindication to iodine-based contrast agents.
Systolic blood pressure > 185 mmHg or diastolic blood pressure > 110 mmHg, and inability to control with antihypertensive medication.
Parallel
Patients with AIS receive intravascular therapy, and within 10 minutes after the surgery, they are administered 100ml of 20% human albumin intravenously (infused within 30 minutes).
DrugWhether to administer albumin to AIS patients after intravascular thrombectomy and reperfusion.
Functional independence Rate
mRS score of 0-2
Rate of independent ambulation
modified Rankin Scale score of 0-3 scores
sICH occurrence
New occurs Intracranial hemorrhage with NIHSS increase \>=4 points
Click on the lead sponsor to view all of their trials.
Tingyu-Yi
Lead sponsor
Zhangzhou Municipal Hospital
Sponsor institution
